Recent studies show adipose-derived stem cells with β-tricalcium phosphate scaffolds boost bone regeneration, offering faster healing and lower costs for aging populations. A new therapy using stem c...
Recent breakthroughs in cancer therapy, including Leo Cancer Care’s proton chair and Moderna’s mRNA vaccines, reduce side effects and improve survival, empowering patients with early detec...
A new OCVA-led clinical trial explores time-restricted eating’s potential to improve mitochondrial function and reduce oxidative stress in early-stage Huntington’s disease patients through circadi...
A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New clinical data on intravenous ...
Breakthrough NLC formulations enhance bioavailability of curcumin and EGCG, demonstrating 40% wrinkle reduction through dual collagen protection and SIRT1 activation, per 2024 clinical trials. Recent ...
Recent studies demonstrate herbal cubosomes enhance bioavailability of arthritis treatments by 40%, with clinical trials and industry partnerships paving the way for commercialization by 2026. Advance...
Emerging research on synthetic peptide BPC-157 shows tendon healing potential, but off-label use for gut and metabolic issues outpaces evidence, raising ethical concerns about peptide accessibility. A...
A new 12-week clinical trial investigates time-restricted eating’s effects on mitochondrial function and symptom onset in early-stage Huntington’s disease patients using advanced digital m...
A Phase I clinical trial (NCT06123456) investigates intravenous BPC-157 for muscle injuries, while regulatory bodies flag safety concerns and potential athletic misuse. Researchers launch the first sa...
A July 2024 pilot study finds intravenous BPC-157 well-tolerated in humans, while EMA and WADA scrutinize its unregulated use in sports medicine and clinics. New human trial data reveals BPC-157’...
